CD19 and diffuse large B-cell lymphoma: Additionally, the humanized anti-CD19 monoclonal antibody tafasitamab in combination with lenalidomide has been approved by international treatment guidelines for the management of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) in patients ineligible for ASCT.